TIDMITX
RNS Number : 7343L
Itaconix PLC
10 September 2019
10 September 2019
Itaconix plc
Unaudited interim results for the 6 month period to 30 June
2019
Commercial Base and Momentum for Long Term Growth
Itaconix plc (AIM: ITX) a leading innovator in sustainable
specialty polymers ("Itaconix" or the "Company"), today announces
its unaudited interim results for the six-month period to 30 June
2019.
Highlights
-- Total revenues for the six-month period were 78% higher than
the first half of 2018 and 23% higher than the second half of 2018.
First half revenues also represent 72% of revenues for the previous
full year.
o Growth was broadly based across the Company's non-phosphate
detergent, odour control, and hair styling polymers.
o Use of our second generation Itaconix(R) CHT(TM) 122 detergent
polymer expanded further in new North American retail accounts
based on the non-phosphate automatic dish detergent formula
licensed to New Wave, as announced in December 2018.
o Use of Itaconix(R) CHT(TM) 122 also expanded into Europe, with
the first use in a non-phosphate detergent announced in May.
o Demand for our ZINADOR(TM) odour removal polymer continues to
expand into leading household brands and new regions through our
collaboration with Croda.
o Revenues for our hairstyling polymer advanced significantly
with both new customers and repeat orders from existing
customers.
-- Gross profits increased by 157% over the first half of 2018
and by 32% over the second half of 2018.
-- Administrative expenses decreased by 52% compared to the
first half of 2018 and by 18% compared to the second half of
2018.
-- Unaudited Adjusted EBITDA(1) was a loss of GBP1.0 million,
compared to a loss of GBP2.5 million for the same period in 2018
and a loss of GBP1.4 million for the second half of 2018,
reflecting the success of the Company's efforts to reduce the
overall cost base while growing revenues.
-- Net cash as at 30 June 2019 was GBP1.5 million, compared to
GBP2.1 million as at 31 December 2018.
-- Important commercial milestones were achieved to support
continued growth with two new global supply agreements with Nouryon
for Itaconix detergent and hair styling polymers.
o Nouryon launched Itaconix's hair styling polymer as Amaze(TM)
SP in April, and subsequently issued its first purchase order to
Itaconix.
-- The Company completed the divestment of its legacy nicotine
gum business in May with the sale of its interest in Alkalon A/S
for GBP0.2 million.
Outlook
Itaconix is in a key stage of broad-based long-term revenue
growth and value creation. From automatic dish detergents and
carpet cleaners to shampoos and underarm deodorants, Itaconix's
proprietary bio-based polymers are emerging as important functional
ingredients in an increasing range of everyday consumer products
for home and personal care. This expanding diversity of uses is
establishing a wide foundation of next generation end-product
formulations for Itaconix products. Collaborations with global
market leaders like Nouryon and Croda are creating opportunities to
convert this foundation into robust revenue growth.
John R. Shaw, Chief Executive Officer, stated: "Our base of
end-product applications combined with our global collaborations is
generating commercial momentum and emerging financial performance
that reflect our near-term goal of sustained revenue growth to
reach profitability. We have a pipeline of active customer projects
to reach beyond this goal, with timing dependent on converting
these projects into order volumes."
(1) Adjusted EBITDA is defined and reconciled to Operating loss
in Note 4 of the Interim Report.
For further information please contact:
Itaconix +1 603 775-4400
John R. Shaw / Laura Denner
N+1 Singer +44 (0) 207 496 3000
Richard Lindley / James Moat (Corporate
Finance)
Mia Gardner (Corporate Broking)
The half-yearly report and this announcement will be available
shortly on the Company's website: www.itaconix.com
Cautionary Statement
Information in this announcement is based upon unaudited
management accounts and, in addition, some of the statements made
are forward looking. Such statements are based on current
expectations at the date of this announcement and are subject to a
number of risks and uncertainties that could cause actual events or
results to differ materially from any expected future events or
results referred to in these forward looking statements. The
Company and its Directors undertake no obligation to update or
revise forward looking statements to reflect any change in
expectations or any change in events, conditions or
circumstances.
Chief Executive's Statement
As I have stated previously, Itaconix's objective is to build a
high gross margin, capital efficient, specialty chemicals company
around the unique value of our proprietary itaconate chemistries.
Our near-term focus is to reach sustaining revenues and
profitability through our current efforts in non-phosphate
detergents, odour control, and hair styling.
We are in a key stage of establishing use of our polymers as
high-value functional ingredients in an increasingly broad base of
everyday consumer products. Our results in the first half of 2019
show that we are making significant progress and gaining critical
recognition of the value of our polymers in a wide range of
end-product formulations:
-- Product demand from large unmet customer needs. The bio-based
content and unique functionality of our proprietary polymers align
closely with major trends and unmet needs in consumer products:
o Safer consumer products. Consumers are increasingly seeking
safer products from sustainable resources that do not persist in
the environment when making buying decisions. In addition,
lawmakers in more and more countries are enacting regulations and
implementing programs for safer and more sustainable products.
Global, specialty, and private-label consumer brands are responding
by reformulating products to keep up with these trends. Itaconix
polymers can meet formulators' needs for new ingredients in a range
of major product categories.
o New product claims. Brands across all spectrums of home and
personal care products compete for customers with new product
claims around price and performance. From odour removal in carpet
cleaners to weightless styling in hair products, the unique
functionalities of Itaconix polymers are enabling formulators to
add new performance claims in a growing range of consumer
products.
o Lower costs. The multiple functionalities of Itaconix polymers
can also reduce direct and indirect product costs by displacing two
or more ingredients in some formulations. For example, formulators
have reduced material, packaging and shipping costs by using one
Itaconix polymer in automatic dish detergents instead of a
traditional chelant and dispersant.
-- High-value functional ingredients. Based on their unique or
multiple functionality, Itaconix polymers are a key ingredient in
determining the performance and value of a wide range of consumer
product formulations. Recent examples of breakthrough consumer
products enabled by Itaconix polymers are:
o A major consumer carpet cleaning brand uses Croda's
ZINADOR(TM) 22L, supplied by Itaconix, to eliminate fresh and
residual odours that are not removed by mere cleaning.
o A specialty detergent brand uses Itaconix(R) CHT(TM) 122 for a
new compact automatic dish detergent pod sold through e-commerce
that saves on shipping costs while still matching national premium
brand performance.
o Nouryon's Amaze(TM) SP, supplied by Itaconix, offers 100%
bio-based content to meet a new trend in weightless hair
styling.
o A specialty personal care brand uses Itaconix odour removal
polymer in its aluminium-free underarm deodorants to eliminate
residues left on clothing.
I believe the existing values that our polymers have established
as key ingredients in everyday consumer products have created the
potential for up to 0.6 grams of Itaconix polymer use per day in a
modern household. Considering the c. 360 million households in
Europe and North America, the addressable annual market based on
this potential is over c. $400 million for our current products.
With further product and application development, I see
opportunities to extend this potential to at least one gram per
day, which would equate to an addressable annual market of c. $700
million.
-- Capital-efficient growth. We are currently in a strong
position to grow with relatively low capital requirements based on
our proprietary production process and our marketing
collaborations. Our existing USA operations have a capacity for up
to c. $15 million of revenues and the ability to double capacity
for a modest investment of c. $0.5 million. Our supply
collaborations allow us to access customer opportunities worldwide
through Nouryon and Croda on mutually favourable terms and to focus
our resources on our strengths in new chemistry and application
development.
Beyond the advancement of our products, we have achieved
additional milestones to date this year including:
-- In May, the Company completed the divestment of its non-core,
legacy nicotine gum business with the sale of its interest in
Alkalon A/S for GBP0.2 million.
-- On September 1(st) , Laura Denner was promoted to Chief
Financial Officer and Michael Norris stepped down as Interim Chief
Financial Officer after a year of service in support of the
restructuring the Company's operations.
As previously reported, we completed exploratory research over
the last five years to extend and broaden the technologies in our
proprietary itaconate chemistry platform. With the progress
underway in our core detergent, odour control, and hair styling
products, we expect to start selectively looking at additional
high-value functional ingredient opportunities within our extensive
itaconate chemistry portfolio.
With our restructuring fully completed, Itaconix is in a key
stage of broad-based long-term revenue growth and value creation.
Our base of end-product applications combined with our global
collaborations is generating commercial momentum and emerging
financial performance that reflect our near-term goal of sustained
revenue growth to reach profitability. We have a pipeline of active
customer projects to reach beyond this goal, with timing dependent
on converting these projects into order volumes.
John R. Shaw
Chief Executive Officer
9 September 2019
Condensed consolidated income statement and statement of
comprehensive income
For the six months ended 30 June 2019
Unaudited Unaudited Audited
6 Months 6 Months Year to
to 30 June to 30 June 31 December
2019 2018 2018
Notes GBP000 GBP000 GBP000
Revenue 5 480 269 660
Cost of sales (341) (215) (555)
----------- ----------- ------------
Gross profit 139 54 105
Other operating income 8 71 96
Administrative expenses (1,304) (2,714) (4,310)
----------- ----------- ------------
Group operating loss (1,157) (2,589) (4,109)
Finance income - 1 3
Exceptional (expense) income
on movement of contingent consideration 6 (644) 38 (2,489)
Exceptional expense on organisational
restructuring 7 - (545) (891)
Gain on sale of equity interest
in associate 8 80 - -
Share of profit of associate 8 - 6 90
----------- ----------- ------------
Loss before tax (1,721) (3,089) (7,396)
Taxation (expense) credit (5) 128 140
----------- ----------- ------------
Loss for the period (1,726) (2,961) (7,256)
Other comprehensive income,
net of income tax
Items that may be reclassified
subsequently to profit or loss:
Exchange differences on translated
foreign operations 30 65 (357)
----------- ----------- ------------
Total comprehensive loss for
the period (1,696) (2,896) (7,613)
=========== =========== ============
Basic and diluted loss per share 9 0.6p 3.8p 4.6p
=========== =========== ============
Condensed consolidated statement of financial position
As at 30 June 2019
Unaudited Audited
As at As at
30 June 31 December
2019 2018
Notes GBP000 GBP000
Non-current assets
Property, plant and equipment 635 719
Right-of-use asset 867 -
Investment in associate undertakings 8 - 131
--------- -----------
1,502 850
Current assets
Inventories 434 303
Trade and other receivables 514 711
Cash and cash equivalents 3 1,572 2,083
--------- -----------
2,520 3,097
--------- -----------
Total assets 4,022 3,947
========= ===========
Financed by
Equity shareholders' funds
Equity share capital 2,686 2,686
Equity share premium 30,301 30,301
Own shares reserve (3) (3)
Merger reserve 20,361 20,361
Share based payment reserve 6,644 6,632
Foreign translation reserve 569 539
Retained earnings (62,059) (60,333)
--------- -----------
Total (deficit) equity (1,501) 183
Non-current liabilities
Contingent consideration 6 3,825 3,052
Long-term lease liability 684 -
--------- -----------
4,509 3,052
--------- -----------
Current liabilities
Trade and other payables 640 478
Short-term lease liability 182 -
Provision for organisational restructuring 7 192 234
--------- -------------
1,014 712
--------- -------------
Total liabilities 5,523 3,764
--------- -------------
Total equity and liabilities 4,022 3,947
========= =============
Interim condensed consolidated statement of cash flows
For the six months ended 30 June 2019
Unaudited Unaudited
6 Months 6 Months
to to
30 June 30 June
2019 2018
GBP000 GBP000
Cash flows from operating activities
Operating loss (1,721) (2,589)
Adjustments for:
Finance expense 1
Depreciation of property, plant and
equipment 84 130
Depreciation of right-of-use asset 84 -
Gain on disposal of equipment (8) -
Gain on sale of investment in associate (80) -
Share option charge 12 129
Revaluation of deferred consideration 644 -
Loss / (gain) on foreign exchange 159 136
Taxation (5) (2)
Increase in inventories (130) (46)
Decrease / (increase) in receivables 198 59
Increase / (decrease) in payables 88 84
--------- ---------
Net cash (outflow) from operating activities (674) (2,099)
--------- ---------
Cash flows from investing activities
Interest received - 1
Investment in associate undertaking 242 (26)
Proceeds from sale of property, plant
and equipment 38 4
Purchase of property, plant and equipment (32) -
--------- ---------
Net cash inflow (outflow) from investing
activities 248 (21)
--------- ---------
Cash flows from financing activities
Lease payments (85) -
--------- ---------
Net cash (outflow) from financing activities (85) -
Net (outflow) in cash and cash equivalents (511) (2,120)
Cash and cash equivalents at beginning
of the period 2,083 3,606
--------- ---------
Cash and cash equivalents at end of
the period 1,572 1,486
========= =========
Notes to the interim condensed consolidated financial
statements
1. General information
These unaudited interim condensed financial statements of
Itaconix plc for the six months ended 30 June 2019 were approved
for issue in accordance with a resolution of the Board on 9
September 2019. Itaconix plc is a public limited company
incorporated in the United Kingdom whose shares are traded on the
AIM Market of the London Stock Exchange.
This half-yearly financial report is also available on the
Group's website at www.itaconix.com.
2. Accounting policies
These interim consolidated financial statements have been
prepared using accounting policies based on International Financial
Reporting Standards (IFRS and IFRIC Interpretations) issued by the
International Accounting Standards Board ("IASB") as adopted for
use in the EU. They do not include all disclosures that would
otherwise be required in a complete set of financial statements and
should be read in conjunction with the 31 December 2018 ('2018')
Annual Report. The financial information for the half years ended
30 June 2019 and 30 June 2018 does not constitute statutory
accounts within the meaning of Section 434 (3) of the Companies Act
2006 and both periods are unaudited.
The annual financial statements of Itaconix Plc ('the Group')
are prepared in accordance with IFRS as adopted by the European
Union. The comparative financial information for the year ended 31
December 2018 included within this report does not constitute the
full statutory Annual Report for that period. The statutory Annual
Report and Financial Statements for 2018 have been filed with the
Registrar of Companies. The Independent Auditors' Report on the
Annual Report and Financial Statements for the year ended 31
December 2018 was unqualified, did draw attention to a matter by
way of emphasis, being going concern, and did not contain a
statement under 498(2) - (3) of the Companies Act 2006.
The interim condensed consolidated financial statements are
presented in sterling and all values are rounded to the nearest
thousand (GBP'000) except when otherwise indicated. The interim
condensed consolidated financial statements are prepared on the
historical cost basis except for contingent consideration which
have been measured at fair value.
New accounting standards
The Group has applied the same accounting policies and methods
of computation in its interim consolidated financial statements as
in its 2018 annual financial statements, except for those that
relate to new standards and interpretations effective for the first
time for periods beginning on (or after) 1 January 2019 and will be
adopted in the 2019 financial statements. New standards impacting
the Group that will be adopted in the annual financial statements
for the year ended 31 December 2019, and which have given rise to
changes in the Group's accounting policies is IFRS 16 "Leases".
Details of the impact of this standard are given below. Other new
and amended standards and interpretations issued by the IASB that
will apply for the first time in the next annual financial
statements are not expected to have a material impact on the
Group.
IFRS 16 "Leases"
The Group adopted IFRS 16 from 1 January 2019, replacing the
existing guidance in IAS 17 - "Leases" (hereafter - "IAS 17"). IFRS
16 changes the existing guidance in IAS 17 and requires lessees to
recognise a lease liability that reflects future lease payments and
a "right-of-use asset" in all lease contracts within scope, with no
distinction between financing and capital leases. IFRS 16 exempts
lessees in short-term leases or when the underlying asset has a low
value. The Group has elected to apply the practical expedient not
to recognise right-of-use assets and lease liabilities for leases
of low-value assets only.
The adoption of IFRS 16 has resulted in the Group recognising
right of use assets and lease liabilities for all contracts that
are, or contain, a lease. For leases historically classified as
operating leases, under legacy accounting requirements the Group
does not recognise related assets or liabilities, disclosing
instead the total commitment in its annual financial statements.
The Group has elected to apply the modified retrospective method.
Therefore, there will be no impact on any comparative accounting
period (interim or annual), with any leases recognised on the
balance sheet on the date of initial application of IFRS 16, being
1 January 2019.
Finally, instead of recognising an operating expense for its
operating lease payments, the Group now recognises interest on its
lease liabilities and amortisation on its right of use assets. This
has increased the reported EBITDA by the amount of its current
operating lease cost, which for 6 months ended 30 June 2019 was
approximately GBP84k.
Going concern
This Interim Report has been prepared on the assumption that the
business is a going concern. In reaching their assessment, the
Directors have considered a period extending at least 12 months
from the date of approval of this half-yearly financial report.
This assessment has included consideration of the forecast
performance of the business for the foreseeable future and the cash
available to the Group. As such, the Directors have concluded that
there exists a material uncertainty which may cast doubt as to the
Group's ability to continue as a going concern. However, taking
account of the Group's working capital at the date of this report,
the Group's current revenue growth, and current shareholder
approval to raise capital if needed, the Directors believe the
Group will continue as a going concern for the foreseeable future.
The interim financial statements do not include the adjustments
that would be required if the Group were unable to continue as a
going concern.
Risks and uncertainties
Itaconix plc's approach to managing the risks and uncertainties
of its business was reported in the Annual Report and Financial
Statements for the year ended 31 December 2018 and is
unchanged.
3. Cash, cash equivalents and investments
Unaudited Audited
As at As at
30 June 31 December
2019 2018
GBP000 GBP000
Cash at bank and in hand 1,572 2,083
--------- -----------
1,572 2,083
========= ===========
4. Reconciliation of Operating Loss to Adjusted EBITDA*
For the purpose of the reconciliation below is to show the
calculation of operating loss to earnings before exceptional costs,
gain on sale of equity interest in associate, share of profit of
associate, interest, taxes, depreciation and amortization (Adjusted
EBITDA).
Unaudited Unaudited Audited
6 Months 6 Months Year to
to 30 June to 30 June 31 December
2019 2018 2018
GBP000 GBP000 GBP000
Loss for the period (1,726) (2,961) (7,256)
Exceptional expense (income) on
movement of contingent consideration 644 (38) 2,489
Exceptional expense on organizational
restructuring - 545 891
Gain on sale of equity interest
in associate (80) - -
Share of profit of associate - (6) (90)
Interest - (1) (3)
Taxes 5 (128) (140)
Depreciation 168 130 222
----------- ----------- --------------
Adjusted EBITDA (989) (2,459) (3,887)
=========== =========== ==============
5. Segmental analysis
Revenue by business segment:
The Group has one segment, the Specialty Chemicals segment,
which designs and manufactures proprietary specialty polymers to
meet customers' needs in the personal and consumer health care,
homecare and industrial sectors. This segment makes up the
continuing operations above.
Net assets of the Group are attributable solely to the UK and
US.
Unaudited Unaudited Audited
6 months 6 months Year to 31
to to December
30 June 2019 30 June 2018 2018
GBP000 GBP000 GBP000
Revenue
Sale of goods 480 269 660
------------- ------------- -----------
Segment revenue 480 269 660
------------- ------------- -----------
Results
Depreciation & amortisation 168 130 202
Segment loss (1,157) (2,589) (4,109)
------------- ------------- -----------
Operating assets 4,022 3,407 3,816
------------- ------------- -----------
Operating liabilities 5,522 2,251 3,764
------------- ------------- -----------
Other disclosure:
Capital expenditure* 32 Nil 436
------------- ------------- -----------
The operating assets exclude the investment in the associate
undertaking.
*Capital expenditure consists of additions of property, plant
and equipment, and intangible assets including assets from the
acquisition of subsidiaries.
Geographical information
Revenue from external customers Net assets
Unaudited Unaudited Audited Unaudited Audited
Six Months Six Months Year to 31 Six Months Year to 31
to to December to December
30 June 2019 30 June 2018 2018 30 June 2019 2018
GBP000 GBP000 GBP000 GBP000 GBP000
Europe 97 76 176 (1,813) 39
North America 383 186 477 312 124
Asia - 7 7 - -
480 269 660 (1,501) 183
============= ============= ========== ============= ==========
The revenue information above is based on the location of the
customer.
6. Contingent consideration
GBP'000
As at 31 December 2018 (Audited) 3,052
Movement in fair value and discounting unwind 644
Movement in foreign exchange 129
-------
As at 30 June 2019 (Unaudited) 3,825
=======
During 2018 in conjunction with the fund raise, a restructuring
of the contingent consideration was executed. The contingent
consideration was restructured into two components:
-- A one-time issue of 15 million new Itaconix plc shares to the Sellers
-- The continuation of the previous contingent consideration
mechanism (i.e. up to $6m in shares), but with the window of time
for potential achievement expanded to the end of 2023 (from the end
of 2020) and including all the revenues of the Group (which are
primarily from products based on the acquired technology in any
event)
It should also be noted that the second component summarised
above is intended to serve as an incentive programme for the two
members of management (John Shaw and Yvon Durant) who are also
Sellers and are entitled to 63% of the total contingent
consideration (in both the existing and proposed construct).
Accordingly, they will not be eligible for any cash bonus or other
share incentive programme for the years 2018 to 2020 inclusive.
Simultaneously the merger agreement with the former shareholders of
Itaconix Corporation and related agreements will be amended to
remove various restrictive clauses, including minimum funding
requirements and employment terms.
Based on the share price at the execution of the restructuring
agreement, the 15m shares had a value of GBP0.3m which was expensed
immediately. The value of the adjusted contingent component using
the latest Board approved forecasts and assumptions as above is
$4.8m or around GBP3.8m.
In respect of 2018, the deferred consideration was valued using
a discounted cash flow-based assessment of the expected sales of
the relevant products extracted from the latest Board approved
forecasts, consistent with the approach in prior years. A discount
rate of 11.2% was used. The valuation includes elements which are
unobservable, and which have a significant impact on the fair
value. Accordingly, contingent consideration is classified as Level
3 fair value measurement.
As a result of the changes in the forecasts, earn out period and
discount rate from the original value assessments, the contingent
consideration at 30 June 2019 was revalued to GBP3,825k.
Sensitivity analysis was also performed, summarised as follows:
-- If the sales in the period 2019 to 2022 were reduced by $1m,
the fair value would be reduced by approximately $40k or around
GBP31k
-- A 1% increase in the discount rate would reduce the fair value by $149k or around GBP118k
Since the forecasts used were a conservative base case, the
computed fair value was deemed appropriate.
7. Provision for organisational restructuring
On June 1, 2018, the Group announced an operational update
regarding the restructuring of its UK subsidiary to focus the
Group's resources on growing revenues of its core products. The
majority of the Group's activities were consolidated into its US
operations, thereby improving the link between product support and
manufacturing. A one-time cost of GBP891k to restructure the UK
subsidiary was recognized in 2018 and was used to pay Director's
and staff redundancy payments, lease termination, and facility
clean-up costs. GBP192k remains outstanding as at 30 June 2019 (30
June 2018: GBP545k) related to these restructuring costs.
8. Investment in associate undertakings
On May 29, 2019 the Group announced the sale of its equity
interest in Alkalon A/S (Alkalon). Alkalon is a Danish speciality
pharma company focused on developing and commercialising medicated
chewing gum formulations. It is a private entity not listed on any
public exchange and there is only one share class in issue
(ordinary shares) so that all shareholders hold the same class of
share with the same rights attached (i.e. there are no restrictions
specific to the Group's holding). The Group's interest in Alkalon
is accounted for using the equity method in the consolidated
financial statements. The Group received a total cash consideration
of approximately DKK 2.0M, equivalent to GBP242k for its 22%
ownership in the Alkalon.
GBP'000
Fair value of Alkalon investment at 31 December 2018
(Audited) 131
Sale of equity interest at 29 May 2019 (131)
-------
Fair value of Alkalon investment at 30 June 2019 (Unaudited) -
=======
9. Weighted-average number of ordinary shares
Unaudited Unaudited
6 Months 6 Months
to to
30 June 30 June
2019 2018
Weighted average number of ordinary shares
for the
purposes of basic and diluted loss per
share ('000) 269,130 78,718
========= =========
10. Events after the reporting period
Subsequent to the reporting period, the Group extended its
current lease on its primary operating facility in Stratham, New
Hampshire, USA for 5 years from September 1, 2019.
11. Cautionary statement
This document contains certain forward-looking statements
relating to Itaconix plc ('the Company'). The Company considers any
statements that are not historical facts as "forward-looking
statements". They relate to events and trends that are subject to
risk and uncertainty that may cause actual results and the
financial performance of the Company to differ materially from
those contained in any forward-looking statement. These statements
are made by the Directors in good faith based on information
available to them and such statements should be treated with
caution due to the inherent uncertainties, including both economic
and business risk factors, underlying any such forward-looking
information.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
IR ZMGGLLLKGLZM
(END) Dow Jones Newswires
September 10, 2019 02:01 ET (06:01 GMT)
Itaconix (LSE:ITX)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Itaconix (LSE:ITX)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
